Cancer Gene Therapy

Human Trials Begin For Antisense Drug

Published in Gene Therapy Weekly, April 5th, 2001

Lorus Therapeutics Inc. announced March 19, 2001, that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to begin a Phase I clinical trial for its anti-cancer drug GTI-2501.

The IND application was based on positive pre-clinical toxicology results for GTI-2501, an antisense compound, which demonstrated that the drug was well tolerated in studies using animals. The findings also suggested that GTI-2501 could be used safely in clinical trials with human patients, at concentration levels that exceed potential therapeutic doses.

"The FDA approval of our IND application allows Lorus to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-04-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry